Description: Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Home Page: www.tenayatherapeutics.com
TNYA Technical Analysis
171 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 825 6900
Officers
| Name | Title |
|---|---|
| Mr. Faraz Ali M.B.A. | CEO, Sec. & Director |
| Dr. Deepak Srivastava M.D. | Scientific Founder, Chairman of Scientific Advisory Board & Director |
| Ms. Leone D. Patterson M.B.A. | Chief Financial & Bus. Officer |
| Dr. Whittemore G. Tingley M.D., PH.D. | Chief Medical Officer |
| Dr. Eric N. Olson Ph.D. | Scientific Founder & Member of Scientific Advisory Board |
| Dr. Bruce R. Conklin | Scientific Founder |
| Dr. Saptarsi Haldar M.D. | Scientific Founder |
| Dr. Sheng Ding | Scientific Founder |
| Dr. Benoit G. Bruneau Ph.D. | Scientific Founder |
| Dr. Kee-Hong Kim Ph.D. | Chief Technology Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8018 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-07-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 140 |